Table 6.
Clinical Characteristics of Patients with Multiple Lung Function Tests (LFTs) Recorded Stratified by Level of Pharmacotherapy Reported
| Clinical Parameters | No Medication (n=25) | SA/LA BA/MA (n=25) | SA/LA BA/MA + ICS (n=63) | p-value |
|---|---|---|---|---|
| Age (years)a | 45.22 (40.12, 50.32) | 56.73 (52.44, 61.02) | 53.13 (50.52, 55.74) | 0.018* |
| Anthropometric data and corpulence status | ||||
| Height (m)a | 1.68 (1.65, 1.72) | 1.68 (1.64, 1.72) | 1.66 (1.64, 1.68) | 0.134 |
| Weight (kg)b | 94 (75, 105) | 71 (58, 91) | 69 (60, 84) | <0.001* |
| Body mass index (BMI, kg/m2)b | 32.61 (25.43, 37.81) | 23.61 (20.44, 32.41) | 25.24 (21.56, 30.39) | 0.042* |
| Underweight (BMI < 18.5 kg/m2)c | 3 (12) | 3 (12) | 9 (14) | 0.939 |
| Normal weight (BMI:18.5–24.9 kg/m2)c | 3 (12) | 10 (40) | 21 (33) | 0.068 |
| Overweight (BMI: 25.0–29.9 kg/m2)c | 3 (12) | 5 (20) | 16 (25) | 0.377 |
| Obese (BMI ≥ 30 kg/m2) c | 16 (64) | 7 (28) | 17 (27) | 0.003* |
| Smoking status | ||||
| Never smokerc | 3 (12) | 0 (0) | 8 (13) | 0.176 |
| Former smokerc | 10 (40) | 8 (32) | 25 (40) | 0.779 |
| Current smokerc | 12 (48) | 17 (68) | 30 (48) | 0.201 |
| Pack Yearsb | 12.5 (5.3, 45) | 17.5 (5, 55.6) | 25 (8.3, 39) | 0.230 |
| Radiology Findings | ||||
| No abnormalityc | 20 (80) | 13 (52) | 24 (38) | 0.002* |
| Any abnormalityc | 5 (20) | 12 (48) | 39 (62) | 0.002* |
| Chronic obstructive pulmonary disease (COPD)c | 2 (8) | 10 (40) | 32 (51) | 0.001* |
| Bronchiectasisc | 3 (12) | 5 (20) | 17 (27) | 0.299 |
| Combined COPD + Bronchiectasisc | 0 (0) | 3 (12) | 10 (16) | 0.109 |
| Mortality | ||||
| Deceasedc | 0 (0) | 1 (4) | 12 (19) | 0.016* |
| Age deceased (years)a | 52.53 | 53.17 (45.67, 60.66) | 0.959 |
Notes: Data were mean (95% confidence interval). P-values were obtained via (a) univariate linear regression for parametrically distributed parameters, (b) univariate quantile regression for non-parametrically distributed parameters, and (c) chi-squared test for categorical parameters. *Statistically significant (p-value <0.05).
Abbreviations: ICS, inhaled corticosteroids; SA/LA BA/MA, short acting/long acting β2 receptor agonist/muscarinic antagonist’.